AFFiRiS AG
🇦🇹Austria
- Country
- 🇦🇹Austria
- Ownership
- Holding
- Established
- 2003-01-01
- Employees
- 101
- Market Cap
- -
- Website
- http://www.affiris.com
Clinical Trials
29
Active:9
Completed:16
Trial Phases
2 Phases
Phase 1:13
Phase 2:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (15 trials with phase data)• Click on a phase to view related trials
Phase 1
13 (86.7%)Phase 2
2 (13.3%)Study Assessing Tolerability and Safety and Exploring the Immunogenicity and Therapeutic Activity of AFFITOPE® PD01A in PD-GBA Patients
Phase 1
Withdrawn
- Conditions
- Parkinson's Disease
- First Posted Date
- 2016-05-02
- Last Posted Date
- 2016-08-05
- Lead Sponsor
- Affiris AG
- Registration Number
- NCT02758730
- Locations
- 🇩🇪
University Hospital Tübingen, Tübingen, Germany
Follow-up Study to Assess a Second Boost Immunization With AFFITOPE® PD01A With Regard to Safety and Clinical Activity (AFF008AA)
Phase 1
Completed
- Conditions
- Parkinson's Disease
- First Posted Date
- 2015-12-02
- Last Posted Date
- 2017-06-05
- Lead Sponsor
- Affiris AG
- Target Recruit Count
- 26
- Registration Number
- NCT02618941
- Locations
- 🇦🇹
Studienzentrum der PROSENEX, AmbulatoriumsbetriebsgesmbH an der Confraternität-Privatklinik Josefstadt, Vienna, Austria
Study Assessing Safety, Immunogenicity and LDLc -Lowering Activity of 2 PCSK9 Targeting AFFITOPE Vaccines in Healthy Subjects
Phase 1
Completed
- Conditions
- Hypercholesterolemia
- First Posted Date
- 2015-07-27
- Last Posted Date
- 2017-10-20
- Lead Sponsor
- Affiris AG
- Target Recruit Count
- 72
- Registration Number
- NCT02508896
- Locations
- 🇦🇹
Medical University of Vienna, Vienna, Austria
Study Assessing Safety and Therapeutic Activity of AFFITOPE® PD01A and PD03A in Patients With Early MSA
Phase 1
Completed
- Conditions
- Neurodegenerative DiseasesMultiple System Atrophy
- First Posted Date
- 2014-10-21
- Last Posted Date
- 2017-06-05
- Lead Sponsor
- Affiris AG
- Target Recruit Count
- 30
- Registration Number
- NCT02270489
- Locations
- 🇫🇷
University Hospital Bordeaux (Pellegrin Hospital), Bordeaux Cedex, France
🇫🇷University Hospital Toulouse, Toulouse Cedex 9, France
Study Assessing Tolerability and Safety of AFFITOPE® PD03A in Patients With Early Parkinson's Disease
Phase 1
Completed
- Conditions
- Neurodegenerative DiseasesParkinson Disease
- First Posted Date
- 2014-10-17
- Last Posted Date
- 2016-10-31
- Lead Sponsor
- Affiris AG
- Target Recruit Count
- 36
- Registration Number
- NCT02267434
- Locations
- 🇦🇹
Medical University Innsbruck, Department of Neurology, Innsbruck, Austria
🇦🇹Studienzentrum der PROSENEX, AmbulatoriumbetriebsgesmbH an der Confraternität -Privatklinik Josefstadt, Vienna, Austria
- Prev
- 1
- 2
- 3
- 4
- Next
News
No news found